UCB Stock Other OTC
Stocks
UCBJF
BE0003739530
Pharmaceuticals
OTC Markets Traded| Market Cap | 42.57B 49.16B 39.69B 36.5B 68.91B 4,674B 69.68B 466B 183B 2,339B 185B 181B 7,746B | P/E 2026 * |
22.8x | P/E 2027 * | 18.5x |
|---|---|---|---|---|---|
| Enterprise Value | 42.79B 49.41B 39.89B 36.69B 69.26B 4,698B 70.03B 469B 184B 2,351B 186B 181B 7,785B | EV / Sales 2026 * |
4.95x | EV / Sales 2027 * | 4.19x |
| Free-Float |
61.59% | Yield 2026 * |
0.65% | Yield 2027 * | 0.67% |
Last Transcript: UCB
| 1 day | -0.39% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 01/01/2015 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 01/07/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/05/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 01/01/2012 | |
| Director/Board Member | 67 | 01/01/2015 | |
| Director/Board Member | 56 | 24/04/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.39% | -.--% | - | - | 49.03B | |
| +1.26% | +10.70% | +35.08% | -0.63% | 75.96B | |
| +1.02% | -3.74% | -7.47% | +21.83% | 47.88B | |
| +1.42% | +9.32% | -50.68% | -50.72% | 43.39B | |
| -0.20% | -0.18% | +57.16% | -23.00% | 30.8B | |
| -0.02% | -4.69% | +55.86% | +86.63% | 24.45B | |
| -0.54% | +3.97% | +106.24% | -44.02% | 22.75B | |
| +4.15% | +0.44% | -2.80% | +175.30% | 19.24B | |
| +0.94% | -0.86% | +68.30% | +167.51% | 16.04B | |
| +1.05% | -6.85% | +60.29% | +117.79% | 15.87B | |
| Average | +0.89% | -0.34% | +35.78% | +50.08% | 32.93B | |
| Weighted average by Cap. | +0.81% | +2.08% | +25.81% | +24.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.64B 9.98B 8.06B 7.41B 13.99B 949B 14.15B 94.69B 37.17B 475B 37.49B 36.66B 1,573B | 9.7B 11.2B 9.04B 8.32B 15.7B 1,065B 15.87B 106B 41.7B 533B 42.06B 41.13B 1,765B |
| Net income | 1.86B 2.15B 1.74B 1.6B 3.01B 204B 3.05B 20.39B 8B 102B 8.07B 7.89B 339B | 2.34B 2.7B 2.18B 2B 3.78B 257B 3.82B 25.6B 10.05B 128B 10.13B 9.91B 425B |
| Net Debt | 216M 249M 201M 185M 349M 23.68B 353M 2.36B 927M 11.85B 935M 915M 39.23B | -1.9B -2.19B -1.77B -1.63B -3.07B -208B -3.11B -20.79B -8.16B -104B -8.23B -8.05B -345B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
